Sonoma Pharmaceuticals (SNOA) Total Current Liabilities (2011 - 2025)

Sonoma Pharmaceuticals' Total Current Liabilities history runs 15 years deep, the most recent figure standing at $4.2 million for Q4 2025.

• In Q4 2025, Total Current Liabilities rose 13.88% year-over-year to $4.2 million; the TTM figure through Dec 2025 stood at $4.2 million (up 13.88% YoY), while the FY2025 annual figure was $4.1 million, up 10.14% from the prior year.
• Total Current Liabilities was $4.2 million for Q4 2025 at Sonoma Pharmaceuticals, down from $4.3 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $5.8 million in Q1 2022 to a low of $3.1 million in Q4 2023.
• Historically, Total Current Liabilities has averaged $4.1 million across 5 years, with a median of $4.0 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities soared 42.69% in 2022, then plunged 36.12% in 2023.
• A 5-year view of Total Current Liabilities shows it stood at $3.9 million in 2021, then climbed by 1.52% to $3.9 million in 2022, then decreased by 21.86% to $3.1 million in 2023, then rose by 20.46% to $3.7 million in 2024, then advanced by 13.88% to $4.2 million in 2025.
• The last three Total Current Liabilities figures came in at $4.2 million (Q4 2025), $4.3 million (Q3 2025), and $4.8 million (Q2 2025), per Business Quant data.